


Principal Investigator/Program Director (Last, First, Middle): Harpole Jr., David H.

BIOGRAPHICAL SKETCHProvide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.

NAME Potti, Anil		POSITION TITLE Research Fellow	
eRA COMMONS USER NAME 			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Christian Medical College, Vellore, India	M.B;B.S	1989 - 1995	Medicine
University of North Dakota School of Medicine, ND	Residency	1997 - 2000	Internal Medicine
University of North Dakota School of Medicine, ND	Chief Resident	2000 - 2001	Internal Medicine
Duke University Medical Center, Durham, NC	Fellowship	2003 - present	Hematology/Oncology

A. Positions and Honors:

- 1989 National Merit Scholar.
- 1995 Rhodes Scholar (Australia).
- 1997 Resident Teacher of the Year – UND School of Medicine.
- 1998 American Society of Clinical Oncology (ASCO) Travel Award.
- 1998 Young Investigator Award - AFMR/CSCR.
- 1998 Research Competition Winner at the Annual ACCP Scientific Meeting.
- 1999 Alpha-Omega-Alpha (AOA) Honor Society Membership.
- 2000 UND Academic & Teaching Excellence Award.
- 2001 Cure for Lymphoma & Lymphoma Research Foundation Award.
- 2001 Young Investigator Award - Central Society of Clinical Research (CSCR)
- 2002 Golden Apple Award (teaching award from medical students).
- 2003 Leonard P. Tow Humanism in Medicine Award.
- 2003 Golden Apple Award (teaching award from medical students).
- 2003 Frank N. Low Prize in Clinical Research.
- 2004 Claus Strohlein Lung Cancer Research Award.
- 2005 Duke Scholar in Genomic Medicine

B. Peer-reviewed publications (in chronological order).

In Press - Withheld

Potti A, Ganti AK, Tuchman SA, Sholes K, Langness E, Koka V, Koch M. HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC). J Carcinog. 2005;4(1):8

Patel P, Henry LL, Ganti AK, **Potti A**. Clinical course of lung cancer in patients with chronic kidney disease. Lung Cancer. 2004;43(3):297-300.

Principal Investigator/Program Director (Last, First, Middle): Harpole Jr., David H.

Potti A, Forseen SE, Koka VK, Pervez H, Koch M, Fraiman G, Mehdi SA, Levitt R. Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. *Cancer Invest.* 2004;22(4):537-44.

Potti A, George DJ. Tyrosine kinase inhibitors in renal cell carcinoma. *Clin Cancer Res.* 2004 Sep 15;10(18 Pt 2):6371-6.

Chen G, Shukeir N, **Potti A**, Sircar K, Aprikian A, Goltzman D, Rabbani SA. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. *Cancer.* 2004 Sep 15;101(6):1345-56.

Potti A, Moazzam N, Langness E, Sholes K, Tendulkar K, Koch M, Kargas S. Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. *Cancer Res* 2004;130(2):80-6.

Potti A, Panwalkar A, Langness E, Sholes K, Tendulkar K, Chittajalu S, Koch M. Role of her-2/neu overexpression and clinical features at presentation as predictive factors in meningiomas. *J Clin Oncol.* 2004 Oct;27(5):452-6

Potti A. HER-2/neu overexpression in colorectal carcinoma. *Gastroenterology.* 2004; 122(1):248-9.

Potti A, Rusconi CP, Sullenger BA, Ortel TL. Regulatable aptamers in medicine. *Expert Opin Biol Ther.* 2004;4(10):1641-7.

Potti A, Ganti AK, Tendulkar K, Sholes K, Chitajallu S, Koch M, Kargas S. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. *J Cancer Res Clin Oncol.* 2003;130(1):52-6.

Potti A, Hille RC, Koch M. Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications. *J Carcinog.* 2003;2(1):8.

Potti A, Mariani P, Saeed M, Smego RA Jr. Residents as researchers: expectations, requirements, and productivity. *Am J Med.* 2003;115(6):510-14.

Potti A, Ganti AK, Sholes K, Langness E, Koka V, Horvarth L, Koch M. Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma. *Clin Cancer Res.* 2003;9(13):4872-6.

Potti A, Moazzam N, Ramar K, Hanekom DS, Kargas S, Koch M. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. *Ann Oncol.* 2003;14(6):894-7.

Foster H, Knox S, Ganti AK, Hebert BJ, Koch M, Tendulkar K, Levitt R, **Potti A**. HER-2/neu overexpression detected by immunohistochemistry in soft tissue sarcomas. *Am J Clin Oncol.* 2003;26(2):188-91.

Potti A, Willardson J, Forseen C, Kishor Ganti A, Koch M, Hebert B, Levitt R, Mehdi SA. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. *Lung Cancer.* 2002;36(3):257-61.

Principal Investigator/Program Director (Last, First, Middle): Harpole Jr., David H.

Abdel-Raheem MM, Potti A, Becker WK, Saberi A, Scilley BS, Mehdi SA. Late adrenal metastasis in operable non-small-cell lung carcinoma. *Am J Clin Oncol*. 2002;25(1):81-3.

Gill N, Malik A, Potti A, Talukdar R, Saberi A, Mehdi SA. HER-2/neu overexpression in colonic malignancies. *Gastroenterology*. 2002;122(1):248-9.

Potti A, Ganti AK, Koch M, Mehdi SA, Levitt R. Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia. *Lung Cancer*. 2001;34(2):227-32.

Potti A, Abdel-Raheem M, Levitt R, Schell DA, Mehdi SA. Intramedullary spinal cord metastases (ISCM) and non-small cell lung carcinoma (NSCLC): clinical patterns, diagnosis and therapeutic considerations. *Lung Cancer*. 2001;31(2-3):319-23.

Pandita D, Steen P, Potti A. Risk factors for deep venous thrombosis of extremities. *Ann Intern Med*. 1997;127(12):1129-32.

C. Research Support
Not Applicable